Talphera TLPH
Talphera FY 2023: net loss $18.4M; diluted EPS −$1.29
- Form
- 10-K
- Filed
- Period
- Importance
- Notable
- Accession
- 0001437749-24-006849
- Document
- 10-K
Key figures from this report
These are the numbers Talphera reported for the year ended Dec 31, 2023, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.
- Net income−$18.4M−139% from $47.8M in FY 202210-K income statement, on EDGAR
- Diluted EPS−$1.29−123% from $5.72 in FY 202210-K income statement, on EDGAR
- Cash and cash equivalents$5.7M−63% from $15.3M in FY 2022Cash and equivalents only; the company page adds short-term investments.10-K balance sheet, on EDGAR
- Cash from operations−$17.5MAgainst −$28.3M in FY 202210-K cash flow statement, on EDGAR
Similar companies
Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.
- Biovie BIVI public float $8M, Dec 31, 2025
- Processa Pharmaceuticals PCSA public float $8M, Jun 30, 2025
- GT Biopharma GTBP public float $9M, Jun 30, 2025
- Orgenesis ORGS public float $8M, Jun 30, 2025
- TherapeuticsMD TXMD public float $9M, Jun 30, 2025
